Flossbach Von Storch SE Takes Position in Zoetis Inc. $ZTS

Flossbach Von Storch SE bought a new position in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,210,978 shares of the company’s stock, valued at approximately $302,601,000. Zoetis comprises approximately 1.4% of Flossbach Von Storch SE’s investment portfolio, making the stock its 24th biggest position.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC increased its stake in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC lifted its position in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co grew its holdings in Zoetis by 11.8% in the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after buying an additional 506 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 3.8%

NYSE ZTS opened at $76.78 on Thursday. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $160.48. The company has a market capitalization of $31.73 billion, a price-to-earnings ratio of 12.65, a PEG ratio of 1.73 and a beta of 0.74. The stock’s 50 day moving average is $75.92 and its two-hundred day moving average is $97.81. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. HSBC decreased their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Finally, TD Cowen cut their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.